Abstract
AbstractCholangiocarcinoma (CCA) is a relatively rare form of cancer arising from epithelial cells lining the biliary tree that connects the liver and gallbladder to the small intestine and can be categorized into intrahepatic CCA (iCCA), perihilar CCA (pCCA), and distal CCA (dCCA). While only surgical resection can provide a cure, most CCAs are detected at inoperable stages and are associated with poor prognosis with median survival of less than two years in patients with advanced stages. Moreover, CCA has a high recurrence rate, even after radical surgery. Therefore, chemotherapy has an important role in the treatment but presently the available systemic medical therapies for advanced and metastatic CCA have very limited efficacy. Even though scientists and physicians have made tremendous efforts to reveal genetic factors of tumor progression and identify CCA specific biomarkers and novel therapeutic targets to develop novel drugs, we are still in the dark when it comes to this cancer. In this chapter, we summarize the latest updates on chemotherapy-based strategies for CCA, and discuss therapeutic targets that may be relevant for the future development of personalized treatments.KeywordsCholangiocarcinomaChemotherapyRecent update
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
